
- /
- Supported exchanges
- / US
- / SLS.NASDAQ
Sellas Life Sciences Group Inc (SLS NASDAQ) stock market data APIs
Sellas Life Sciences Group Inc Financial Data Overview
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Sellas Life Sciences Group Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sellas Life Sciences Group Inc data using free add-ons & libraries
Get Sellas Life Sciences Group Inc Fundamental Data
Sellas Life Sciences Group Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sellas Life Sciences Group Inc News

Sellas Life Sciences files to sell 19.69M shares of common stock for holders
* Sellas Life Sciences (SLS [https://seekingalpha.com/symbol/SLS]) has filed to sell 19,685,040 shares of common stock for holders. * This prospectus is not an offer to sell these securities. * ...


Copper Supply Disruptions Might Change The Case For Investing In Solaris Resources (TSX:SLS)
RBC Capital Markets recently noted that copper equities saw robust gains after production disruptions at major mines like Freeport's Grasberg and Codelco's El Teniente tightened global copper supply a...

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...

Solaris Strengthens Community Partnerships and Advances Key Milestones at Warintza Project
HIGHLIGHTS: Landmark agreement signed with PSHA, completing formal partnerships with all Indigenous organisations surrounding the Warintza Project Pre-Feasibility Study advancing with positive moment...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.